The first-line treatment in patients with metastatic disease includes systemic therapy by using multitarget tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors. This evidence concerns the gene MTOR and metastatic neoplasm.